These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 18843565)

  • 21. [Aripiprazole for the treatment of Tourette syndrome. Experience in 10 patients].
    Miranda C M; Castiglioni T C
    Rev Med Chil; 2007 Jun; 135(6):773-6. PubMed ID: 17728905
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [A control study of aripiprazole and tiapride treatment for tic disorders in children].
    Liu YY; Chen YH; Chen H; Liu ZS
    Zhongguo Dang Dai Er Ke Za Zhi; 2010 Jun; 12(6):421-4. PubMed ID: 20540847
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aripiprazole: new drug. Just another neuroleptic.
    Prescrire Int; 2005 Oct; 14(79):163-7. PubMed ID: 16285069
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.
    Potkin SG; Saha AR; Kujawa MJ; Carson WH; Ali M; Stock E; Stringfellow J; Ingenito G; Marder SR
    Arch Gen Psychiatry; 2003 Jul; 60(7):681-90. PubMed ID: 12860772
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole.
    Lu ML; Shen WW; Chen CH
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1978-81. PubMed ID: 18848860
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aripiprazole in children and adolescents with Tourette's disorder: an open-label safety and tolerability study.
    Lyon GJ; Samar S; Jummani R; Hirsch S; Spirgel A; Goldman R; Coffey BJ
    J Child Adolesc Psychopharmacol; 2009 Dec; 19(6):623-33. PubMed ID: 20035580
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardiovascular safety of aripiprazole and pimozide in young patients with Tourette syndrome.
    Gulisano M; Calì PV; Cavanna AE; Eddy C; Rickards H; Rizzo R
    Neurol Sci; 2011 Dec; 32(6):1213-7. PubMed ID: 21732066
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of tics in tourette syndrome with aripiprazole.
    Kastrup A; Schlotter W; Plewnia C; Bartels M
    J Clin Psychopharmacol; 2005 Feb; 25(1):94-6. PubMed ID: 15643108
    [No Abstract]   [Full Text] [Related]  

  • 29. [Multiple tics and Gilles de la Tourette syndrome].
    Müller K
    Monatsschr Kinderheilkd; 1991 Jun; 139(6):330-5. PubMed ID: 1680219
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cannabis-based medicine in treatment of patients with Gilles de la Tourette syndrome.
    Szejko N; Saramak K; Lombroso A; Müller-Vahl K
    Neurol Neurochir Pol; 2022; 56(1):28-38. PubMed ID: 34708399
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacological treatment of tic disorders and Tourette Syndrome.
    Roessner V; Schoenefeld K; Buse J; Bender S; Ehrlich S; Münchau A
    Neuropharmacology; 2013 May; 68():143-9. PubMed ID: 22728760
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Case series on the use of aripiprazole for Tourette syndrome.
    Murphy TK; Bengtson MA; Soto O; Edge PJ; Sajid MW; Shapira N; Yang M
    Int J Neuropsychopharmacol; 2005 Sep; 8(3):489-90. PubMed ID: 15857570
    [No Abstract]   [Full Text] [Related]  

  • 33. The neurocognitive effects of aripiprazole compared with risperidone in the treatment of schizophrenia.
    Sato G; Yoshimura S; Yamashita H; Okamoto Y; Yamawaki S
    Hiroshima J Med Sci; 2012 Dec; 61(4):75-83. PubMed ID: 23342824
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Distinct structural changes underpin clinical phenotypes in patients with Gilles de la Tourette syndrome.
    Worbe Y; Gerardin E; Hartmann A; Valabrégue R; Chupin M; Tremblay L; Vidailhet M; Colliot O; Lehéricy S
    Brain; 2010 Dec; 133(Pt 12):3649-60. PubMed ID: 20959309
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An open-label study of the efficacy and tolerability of aripiprazole for children and adolescents with tic disorders.
    Yoo HK; Choi SH; Park S; Wang HR; Hong JP; Kim CY
    J Clin Psychiatry; 2007 Jul; 68(7):1088-93. PubMed ID: 17685747
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Deep brain stimulation for Gilles de la Tourette syndrome: a case series targeting subregions of the globus pallidus internus.
    Martínez-Fernández R; Zrinzo L; Aviles-Olmos I; Hariz M; Martinez-Torres I; Joyce E; Jahanshahi M; Limousin P; Foltynie T
    Mov Disord; 2011 Aug; 26(10):1922-30. PubMed ID: 21538528
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Gilles de la Tourette-syndrome: treatment of a neuropsychiatric disorder].
    Kawohl W
    Praxis (Bern 1994); 2010 Nov; 99(22):1353-60. PubMed ID: 21049442
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aripiprazole in schizophrenia and schizoaffective disorder: A review.
    Stip E; Tourjman V
    Clin Ther; 2010; 32 Suppl 1():S3-20. PubMed ID: 20152550
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Medications for stimulant abuse: agonist-based strategies and preclinical evaluation of the mixed-action D-sub-2 partial agonist aripiprazole (Abilify).
    Bergman J
    Exp Clin Psychopharmacol; 2008 Dec; 16(6):475-83. PubMed ID: 19086768
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pimozide for tics in Tourette's syndrome.
    Pringsheim T; Marras C
    Cochrane Database Syst Rev; 2009 Apr; 2009(2):CD006996. PubMed ID: 19370666
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.